Windlas Biotech Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Komal Gupta

Chief executive officer

₹16.5m

Total compensation

CEO salary percentage	n/a
CEO tenure	9.1yrs
CEO ownership	n/a
Management average tenure	4.6yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO

Komal Gupta

9.1yrs

Tenure

₹16,530,000

Compensation

Mrs. Komal Gupta is the Chief Financial Officer of Windlas Biotech Limited since October 16, 2015 and serves as its Chief Executive Officer since February 08, 2023. She joined Windlas Biotech on October 16...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Komal Gupta	CFO & CEO	9.1yrs	₹16.53m	no data
Ananta Panda	Company Secretary & Compliance Officer	3.6yrs	₹2.52m	no data
Ashok Windlass	Whole-Time Director	no data	₹15.60m	62.51% ₹ 12.5b
Hitesh Windlass	MD & Executive Director	4.6yrs	₹17.50m	0.000010% ₹ 2.0k
Manoj Windlass	Joint MD & Executive Director	4.6yrs	₹17.50m	0.000030% ₹ 6.0k
Pawan Sharma	Executive Director	no data	₹5.07m	no data
Mohammed Aslam	President of Sales & Marketing	no data	no data	no data
Om Sule	Site Quality Head	4.9yrs	no data	no data

4.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 543329's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ashok Windlass	Whole-Time Director	23.8yrs	₹15.60m	62.51% ₹ 12.5b
Hitesh Windlass	MD & Executive Director	16.8yrs	₹17.50m	0.000010% ₹ 2.0k
Manoj Windlass	Joint MD & Executive Director	18.6yrs	₹17.50m	0.000030% ₹ 6.0k
Pawan Sharma	Executive Director	5.4yrs	₹5.07m	no data
Gaurav Gulati	Non-Executive Independent Director	3.5yrs	₹540.00k	no data
Vivek Dhariwal	Non-Executive Independent Chairman	3.5yrs	₹380.00k	no data
Srinivasan Venkataraman	Non-Executive Independent Director	3.5yrs	₹450.00k	no data
Prachi Windlass	Non-Executive Director	3.5yrs	no data	0.000010% ₹ 2.0k

4.5yrs

Average Tenure

49yo

Average Age

Experienced Board: 543329's board of directors are considered experienced (4.5 years average tenure).

Windlas Biotech Management

Management criteria checks 3/4

Key information

Recent management updates

Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024

Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024

Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023

Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer

Less than half of directors are independent

Windlas Biotech Limited, Annual General Meeting, Sep 19, 2022

Recent updates

Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024)

New minor risk - Share price stability

Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24

Dividend increased to ₹5.50

Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024

Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024)

Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023)

Now 21% overvalued after recent price rise

Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024

Now 21% overvalued after recent price rise

Now 20% overvalued after recent price rise

Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023)

Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024

Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024

Investor sentiment improves as stock rises 22%

Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023)

Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023

Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23

Upcoming dividend of ₹4.00 per share at 1.1% yield

Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023)

Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022)

Windlas Biotech Limited Recommends Dividend

Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer

Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022)

Less than half of directors are independent

Windlas Biotech Limited (BSE:543329) announces an Equity Buyback for INR 250 million worth of its shares.

Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022)

Windlas Biotech Limited Declares A Final Dividend for the Financial Year 2021-22

Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2021-22

Windlas Biotech Limited, Annual General Meeting, Sep 19, 2022

First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022)

Windlas Biotech Limited to Report Q1, 2023 Results on Aug 04, 2022

The Board of Directors of Windlas Biotech Limited, At Their Meeting Held on May 12, 2022, Approves the Dividend of INR 3.5 Per Share

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age